IP Library Granted Patent US 12,364,276
Granted Patent B2
US 12,364,276 · App. 17/689,927 · Granted Jul 22, 2025

Probiotic for inhibiting growth of

Inventors: Xuejun Li (Taizhou, CN); Gordon Zhang (Taizhou, CN); Yu Zhao (Taizhou, CN); Chengwei Xu (Taizhou, CN)
Assignee: IVC NUTRITION CORPORATION
A23L33/135A61K35/745A61K35/747A61P9/10A61P31/04A23V2400/113A23V2400/125A23V2400/143A23V2400/165A23V2400/169A23V2400/173A23V2400/175A23V2400/515A23V2400/517A23V2400/529
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,276
App. No.
17/689,927
Granted
Jul 22, 2025
Kind
B2
Abstract

A probiotic for inhibiting growth of Proteus mirabilis , including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

Claims (29)

1. A method for inhibiting growth of Proteus mirabilis in a subject, comprising:

administering a probiotic to the subject;

wherein the probiotic comprises a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof; and

the Lactobacillus rhamnosus is Lactobacillus rhamnosus AI-11 assigned accession CGMCC No. 21745;

the Lactobacillus fermentum is Lactobacillus fermentum AI-25 assigned accession CGMCC No. 21746;

the Lactobacillus plantarum is Lactobacillus plantarum AI-66 assigned accession CGMCC No. 21741;

the Lactobacillus casei is Lactobacillus casei AI-12 assigned accession CGMCC No. 21742;

the Lactobacillus acidophilus is Lactobacillus acidophilus AI-32 assigned accession CGMCC No. 21743;

the Lactobacillus paracasei is Lactobacillus paracasei AI-62 assigned accession CGMCC No. 21744;

the Lactobacillus reuteri is Lactobacillus reuteri AI-70 assigned accession CGMCC No. 21748;

the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis AI-01 assigned accession CGMCC No. 21747;

the Bifidobacterium infantis is Bifidobacterium infantis AI-20 assigned accession CGMCC No. 21779; and

the Bifidobacterium bifidum is Bifidobacterium bifidum AI-91 assigned accession CGMCC No. 21780.

2. The method of claim 1 , wherein the probiotic is a combination of the Lactobacillus rhamnosus and the Lactobacillus fermentum , a combination of the Lactobacillus casei and the Bifidobacterium animalis subsp. Lactis , or a combination of the Lactobacillus paracasei and the Bifidobacterium infantis.

3. A method for treating atherosclerosis in a subject in need thereof, comprising:

inoculating a probiotic into a fermentation medium followed by anaerobic culture to obtain a fermentation broth; and

administering a therapeutically effective amount of the fermentation broth to the subject;

wherein the probiotic comprises a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof; and

the Lactobacillus rhamnosus is Lactobacillus rhamnosus AI-11 assigned accession CGMCC No. 21745;

the Lactobacillus fermentum is Lactobacillus fermentum AI-25 assigned accession CGMCC No. 21746;

the Lactobacillus plantarum is Lactobacillus plantarum AI-66 assigned accession CGMCC No. 21741;

the Lactobacillus casei is Lactobacillus casei AI-12 assigned accession CGMCC No. 21742;

the Lactobacillus acidophilus is Lactobacillus acidophilus AI-32 assigned accession CGMCC No. 21743;

the Lactobacillus paracasei is Lactobacillus paracasei AI-62 assigned accession CGMCC No. 21744;

the Lactobacillus reuteri is Lactobacillus reuteri AI-70 assigned accession CGMCC No. 21748;

the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis AI-01 assigned accession CGMCC No. 21747;

the Bifidobacterium infantis is Bifidobacterium infantis AI-20 assigned accession CGMCC No. 21779; and

the Bifidobacterium bifidum is Bifidobacterium bifidum AI-91 assigned accession CGMCC No. 21780.

4. The method of claim 3 , wherein the probiotic is a combination of the Lactobacillus rhamnosus and the Lactobacillus fermentum , a combination of the Lactobacillus casei and the Bifidobacterium animalis subsp. Lactis , or a combination of the Lactobacillus paracasei and the Bifidobacterium infantis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2023
From: LI, XUEJUN; ZHANG, GORDON; ZHAO, YU; XU, CHENGWEI
To: ALAND BIOTECHNOLOGY RESEARCH TAIZHOU CO., LTD
Reel/Frame 062609/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2023
From: ALAND BIOTECHNOLOGY RESEARCH TAIZHOU CO., LTD
To: IVC NUTRITION CORPORATION
Reel/Frame 062609/0866 →
Priority Claims (1)
CN 202110530026.7 · May 14, 2021 · national
Continuity (2)
Continuation PCTCN2021102388 · Jun 25, 2021
Related Publication 20220192247A1 · Jun 23, 2022
References Cited (6)
US 10058576B2 · Bushman · 2018 [cited by examiner]
CN 105189732A · 2015 [cited by examiner]
CN 109223832A · 2019 [cited by applicant]
CN 110257306A · 2019 [cited by applicant]
CN 110621332A · 2019 [cited by applicant]
JP 2017201983A · 2017 [cited by applicant]